Journal
BIOMARKERS
Volume 19, Issue 3, Pages 222-230Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/1354750X.2014.897757
Keywords
Acetaminophen; diagnosis; hepatotoxicity; mitochondria; prognosis
Categories
Funding
- McNeil Consumer Health, Inc.
- University of Kansas Medical Center Liver Center
- National Institutes of Health [R01 DK070195, R01 AA12916, R44 DK074205]
- National Center for Research Resources [5P20RR021940-07]
- National Institute of General Medical Sciences of the National Institutes of Health [8 P20 GM103549-07]
- Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health [P20 GM12345]
- National Institute of Environmental Health Sciences [T32 ES007079-26A2]
Ask authors/readers for more resources
Context: New biomarkers are needed in acetaminophen (APAP) hepatotoxicity. Plasma argininosuccinate synthetase (ASS) is a promising candidate. Objective: Characterize ASS in APAP hepatotoxicity. Methods: ASS was measured in plasma from rodents and humans with APAP hepatotoxicity. Results: In mice, ASS increased before injury, peaked before alanine aminotransferase (ALT) and decreased rapidly. Fischer rats had a greater increase in ASS relative to ALT. Patients with abnormal liver test results had very high ASS compared to controls. ASS appeared to increase early in some patients, and declined rapidly in all. Conclusions: ASS may be a useful biomarker of acute cell death in APAP hepatotoxicity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
